
Clinical research blog
Explore our blog for insights into the big questions in precision medicine and clinical research.
Effectively balancing the essential role of ethical and legal regulations with the challenges of patient finding and enrollment within a complex and competitive landscape requires a proactive approach. In this blog, we'll outline key approaches to achieving balance:
Growing numbers of rare disease clinical trials mean it’s never been more important to ensure that patient recruitment campaigns are identifying the right patients in support of the future of treatment development. However, conversion and compliance can feel increasingly in conflict when stringent regulations present barriers to participation.
In last week’s episode of The Genetics Podcast, Patrick Short spoke with Dr. Eric Adler, Professor of Medicine at UC San Diego and Chief Medical Officer at Lexeo Therapeutics. Dr. Adler’s work bridges the gap between cutting-edge gene therapy research and patient-centered cardiology, particularly for those with genetic heart diseases like Danon disease.
In last week’s episode of The Genetics Podcast, Patrick sat down with Dr. Versha Pleasant, Clinical Assistant Professor at the University of Michigan and Director of the Cancer Genetics and Breast Health Clinic at the Von Voigtlander Women’s Hospital. Versha’s work focuses on addressing racial health disparities, particularly in breast cancer outcomes for Black women, and expanding access to genetic testing and counseling.
Patient recruitment efforts are often designed with the best of intentions, incorporating processes that fulfill every regulatory requirement. However, without effective conversion, the time, money, and effort invested in building a recruitment strategy can fall short. Although recruitment workflows may look ideal from a research perspective, lacking a strong patient experience in the design process can lead to missed opportunities in onboarding motivated patients.
On October 18th, 2024 20/20 Onsite, Sano Genetics, and Clinical Enrollment announced the launch of a new partnership to offer a comprehensive solution for identifying and screening potential participants for Inherited Retinal Disease (IRD) clinical trials. (Read more here.)
In a recent episode of The Genetics Podcast, Patrick Short is joined by Dr. Jonathon Hill, Associate Professor at Brigham Young University and Co-Founder and VP of Science and Technology at Wasatch Biolabs. Together, they explore how long-read sequencing and epigenetic biomarkers are changing the game in diagnostics and how Jonathon is helping to build a thriving biotech community in Utah.
Effective data management and innovative clinical trial designs are pivotal in advancing precision medicine, particularly for biotech companies operating with budget constraints. By implementing robust data management systems, maximizing data reuse and sharing, and adopting cost-effective clinical trial methodologies, biotechs can enhance research efficiency, reduce operational costs, and accelerate the development of personalized therapies.
We were excited to welcome Angela Bradshaw, Director of Research at Alzheimer Europe, to The Genetics Podcast this week. Angela shared her journey from academic research to collaborating on initiatives that tackle Alzheimer’s disease and dementia across Europe. With a career spanning oncology and gene therapy, and a personal connection to rare diseases and dementia, Angela offered a unique perspective on the challenges and opportunities in dementia research, diagnostics, and care.
Today’s biotech market has never been more competitive, so the ability to innovate quickly and efficiently is a critical success factor. To achieve this, some organizations have turned to agile methodologies, open-source solutions, and advanced analytics powered by artificial intelligence (AI). By strategically integrating these approaches, biotech companies can enhance research productivity, control expenditures, and ultimately bring new precision medicine therapies to market more rapidly.